Narrative review / 2012
Advanced lipoprotein analysis measures have not been shown to improve cardiovascular outcomes beyond standard risk factors and statin-guided LDL reduction.
Practitioners sometimes utilize advanced lipoprotein analysis to predict risk and individualize lifestyle and drug therapy. However, measures such as LDL and HDL particle number and size, apolipoproteins B and A, and lipoprotein(a) have not met biomarker evaluation standards, and it remains undetermined if they incrementally add to traditional risk factor prediction or improve outcomes. Furthermore, medications like niacin and fenofibrate that alter these parameters failed to show additional cardiovascular risk reduction in recent randomized trials of high-risk patients on statins. The authors note that focusing on LDL cholesterol reduction and statin therapy intensification remains supported by a large body of evidence.
- Study type
- Narrative review
- Who was studied
- Patients evaluated for cardiovascular prevention
- What was measured
- Clinical utility of advanced lipoprotein analysis in cardiovascular risk reduction
THE PAPER
What is the role of advanced lipoprotein analysis in practice?
Robinson JG. J Am Coll Cardiol, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.